Risk of Malignancies in Patients With Rheumatoid Arthritis Treated With Biologic Therapy

2012295 citationsReview

Authors

María A. López-Olivo · The University of Texas MD Anderson Cancer Center

Jean Tayar · General Department of Preventive Medicine

Juan Antonio Martínez-López · Spanish Society of Hematology and Hemotherapy

Eduardo N. Pollono · Texas Tech University

Jose Polo Cueto

M. Rosa Gonzales-Crespo · Universidad Complutense de Madrid

Stephanie Fulton · The University of Texas MD Anderson Cancer Center

Abstract

The use of BRMs among patients with RA included in RCTs of at least 6 months' duration was not significantly associated with an increased risk of malignancy compared with other disease-modifying antirheumatic drugs or with placebo.

Topics & Keywords

Rheumatoid Arthritis Research and Therapies Chronic Lymphocytic Leukemia Research Lymphoma Diagnosis and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: JAMA

Volume 308, Issue 9, pp. 898-898

DOI: 10.1001/2012.jama.10857

Field-Weighted Citation Impact: 24.78